Differentiating effects of levodopa and subthalamic nucleus deep brain stimulation on motor features in Parkinson disease
Differentiating effects of levodopa and subthalamic nucleus deep brain stimulation on motor features in Parkinson disease
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
A plain-language reading has not been prepared for this paper yet.
Original abstract
While deep brain stimulation of the subthalamic nucleus (STN DBS) is traditionally used to treat motor fluctuations in Parkinson disease (PD), recent progress in levodopa delivery systems may offer non-invasive alternatives to surgical options. To gain insight into symptoms more likely to be treated effectively by STN DBS or levodopa, we systematically compared the differential effects of levodopa and STN-DBS on specific parkinsonian motor components.We retrospectively analyzed 395 PD patients who received bilateral STN-DBS at Washington University (1999-2020). UPDRS-III was obtained in three conditions: preoperative OFF-medication, preoperative ON-medication, and postoperative ON-DBS/OFF-medication. Exploratory factor analysis identified a consensus structure across conditions. Treatment responses by factor were compared using Wilcoxon rank-sum tests and correlations were assessed with Kendall's tau.Both treatments significantly improved all motor features. STN-DBS showed slightly superior efficacy for upper body tremor (mean change: -3.84 vs -3.43, p < 0.001), while levodopa demonstrated much greater effectiveness for axial symptoms (-5.41 vs -2.65, p < 0.001), and slightly greater effectiveness for lower body tremor (-1.25 vs -1.06, p < 0.001), and lower body bradykinesia (-1.18 vs -0.91, p = 0.005). Correlations between treatment responses were weak but statistically significant for rigidity (τ = 0.158), bradykinesia (hand: τ = 0.118; leg: τ = 0.179), and axial symptoms (τ = 0.207).Levodopa and STN-DBS demonstrate similar but distinct therapeutic profiles across parkinsonian motor domains. However, weak correlations between treatment modalities for all motor features challenge the utility of levodopa responsiveness for DBS candidacy and support individualization of treatment selection based on symptom profile.